

SECOND REGULAR SESSION

HOUSE BILL NO. 1952

96TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES SCHATZ (Sponsor), LICHTENEGGER, RICHARDSON, HOUGHTON, PHILLIPS, LANT, REIBOLDT, HINSON, DENISON, BROWN (85), FUHR, KLIPPENSTEIN, REDMON, FISHER, STREAM, KELLEY (126), KORMAN, CAUTHORN, FITZWATER, CONWAY (14), LAIR, SOLON, HIGDON, PIERSON, BLACK, FRANKLIN, SMITH (71), ELLINGER, ATKINS, MONTECILLO, WEBB, BROWN (50), CASEY, WALTON GRAY, HUMMEL, RIZZO, PACE, McMANUS, MORGAN, MAY, CARLSON, GOSEN, HAMPTON AND MCGHEE (Co-sponsors).

6164L.011

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to the meth lab elimination act, with penalty provisions and an expiration date.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 14 (d) Alphacetylmethadol;
- 15 (e) Alphameprodine;
- 16 (f) Alphamethadol;
- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxyin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;

- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;

- 86 (r) Myrophine;
87 (s) Nicocodeine;
88 (t) Nicomorphine;
89 (u) Normorphine;
90 (v) Pholcodine;
91 (w) Thebacon;
92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
98 (c) 2,5-dimethoxyamphetamine;
99 (d) 2,5-dimethoxy-4-ethylamphetamine;
100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
101 (f) 4-methoxyamphetamine;
102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
104 (i) 3,4-methylenedioxyamphetamine;
105 (j) 3,4-methylenedioxymethamphetamine;
106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
108 (m) 3,4,5-trimethoxyamphetamine;
109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
110 isomers;
- 111 (o) Alpha-ethyltryptamine;
112 (p) Alpha-methyltryptamine;
113 (q) Bufotenine;
114 (r) Diethyltryptamine;
115 (s) Dimethyltryptamine;
116 (t) 5-methoxy-N,N-diisopropyltryptamine;
117 (u) Ibogaine;
118 (v) Lysergic acid diethylamide;
119 (w) Marijuana or marihuana;
120 (x) Mescaline;
121 (y) Parahexyl;

- 122 (z) Peyote, to include all parts of the plant presently classified botanically as *Lophophora*
123 *Williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
124 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
125 its seed or extracts;
- 126 (aa) N-ethyl-3-piperidyl benzilate;
- 127 (bb) N-methyl-3-piperidyl benzilate;
- 128 (cc) Psilocybin;
- 129 (dd) Psilocyn;
- 130 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis*
131 (*cannabis* plant), as well as synthetic equivalents of the substances contained in the *cannabis*
132 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
133 isomers with similar chemical structure and pharmacological activity to those substances
134 contained in the plant, such as the following:
- 135 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 136 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 137 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 138 d. Any compounds of these structures, regardless of numerical designation of atomic
139 positions covered;
- 140 (ff) Ethylamine analog of phencyclidine;
- 141 (gg) Pyrrolidine analog of phencyclidine;
- 142 (hh) Thiophene analog of phencyclidine;
- 143 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 144 (jj) *Salvia divinorum*;
- 145 (kk) Salvinorin A;
- 146 (ll) Synthetic cannabinoids:
- 147 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
148 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by
149 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
150 or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
151 extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited
152 to:
- 153 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
- 154 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
- 155 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
- 156 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
- 157 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;

- 158 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
159 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
160 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
161 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
162 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
163 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
164 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- 165 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the
166 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
167 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
168 substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any
169 extent;
- 170 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution
171 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
172 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or
173 not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl
174 ring to any extent;
- 175 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the
176 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
177 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
178 substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any
179 extent. Including, but not limited to:
- 180 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
181 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
182 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
183 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
184 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- 185 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
186 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
187 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or
188 not substituted in the cyclohexyl ring to any extent. Including, but not limited to:
- 189 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-
190 hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5, and homologues
191 where side chain n=4,6, or 7;
- 192 f. Any compound containing a 3-(benzoyl)indole structure with substitution at the
193 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

194 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
195 substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to
196 any extent. Including, but not limited to:

197 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;

198 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;

199 g . C P 5 0 , 5 5 6 - 1 , o r
200 [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a
201 ,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

202 h . H U - 2 1 0 , o r
203 (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
204 a-tetrahydrobenzo[c]chromen-1-ol;

205 i . H U - 2 1 1 , o r
206 Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl
207)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

208 j . C P 5 0 , 5 5 6 - 1 , o r
209 [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a
210 ,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

211 k. Dimethylheptylpyran, or DMHP;

212 (5) Any material, compound, mixture or preparation containing any quantity of the
213 following substances having a depressant effect on the central nervous system, including their
214 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
215 isomers is possible within the specific chemical designation:

216 (a) Gamma-hydroxybutyric acid;

217 (b) Mecloqualone;

218 (c) Methaqualone;

219 (6) Any material, compound, mixture or preparation containing any quantity of the
220 following substances having a stimulant effect on the central nervous system, including their
221 salts, isomers and salts of isomers:

222 (a) Aminorex;

223 (b) N-benzylpiperazine;

224 (c) Cathinone;

225 (d) Fenethylamine;

226 (e) 3-Fluoromethcathinone;

227 (f) 4-Fluoromethcathinone;

228 (g) Mephedrone, or 4-methylmethcathinone;

229 (h) Methcathinone;

- 230 (i) 4-methoxymethcathinone;
- 231 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 232 (k) M e t h y l e n e d i o x y p y r o v a l e r o n e , M D P V , o r
- 233 (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;
- 234 (l) Methylone, or 3,4-Methylenedioxy-methcathinone;
- 235 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
- 236 (n) N-ethylamphetamine;
- 237 (o) N,N-dimethylamphetamine;
- 238 (7) A temporary listing of substances subject to emergency scheduling under federal law
- 239 shall include any material, compound, mixture or preparation which contains any quantity of the
- 240 following substances:
- 241 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
- 242 salts and salts of isomers;
- 243 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
- 244 optical isomers, salts and salts of isomers;
- 245 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
- 246 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
- 247 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 248 3. The department of health and senior services shall place a substance in Schedule II
- 249 if it finds that:
- 250 (1) The substance has high potential for abuse;
- 251 (2) The substance has currently accepted medical use in treatment in the United States,
- 252 or currently accepted medical use with severe restrictions; and
- 253 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 254 4. The controlled substances listed in this subsection are included in Schedule II:
- 255 (1) Any of the following substances whether produced directly or indirectly by extraction
- 256 from substances of vegetable origin, or independently by means of chemical synthesis, or by
- 257 combination of extraction and chemical synthesis:
- 258 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
- 259 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
- 260 nalmefene, naloxone and naltrexone, and their respective salts but including the following:
- 261 a. Raw opium;
- 262 b. Opium extracts;
- 263 c. Opium fluid;
- 264 d. Powdered opium;
- 265 e. Granulated opium;

- 266 f. Tincture of opium;
267 g. Codeine;
268 h. Ethylmorphine;
269 i. Etorphine hydrochloride;
270 j. Hydrocodone;
271 k. Hydromorphone;
272 l. Metopon;
273 m. Morphine;
274 n. Oxycodone;
275 o. Oxymorphone;
276 p. Thebaine;
277 (b) Any salt, compound, derivative, or preparation thereof which is chemically
278 equivalent or identical with any of the substances referred to in this subdivision, but not
279 including the isoquinoline alkaloids of opium;
280 (c) Opium poppy and poppy straw;
281 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
282 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
283 with any of these substances, but not including decocainized coca leaves or extractions which
284 do not contain cocaine or ecgonine;
285 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
286 or powder form which contains the phenanthrene alkaloids of the opium poppy);
287 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
288 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
289 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
290 (a) Alfentanil;
291 (b) Alphaprodine;
292 (c) Anileridine;
293 (d) Bezitramide;
294 (e) Bulk dextropropoxyphene;
295 (f) Carfentanil;
296 (g) Dihydrocodeine;
297 (h) Diphenoxylate;
298 (i) Fentanyl;
299 (j) Isomethadone;
300 (k) Levo-alphaacetylmethadol;
301 (l) Levomethorphan;

- 302 (m) Levorphanol;
303 (n) Metazocine;
304 (o) Methadone;
305 (p) Meperidine;
306 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
307 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
308 acid;
309 (s) Pethidine (meperidine);
310 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
311 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
312 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
313 (w) Phenazocine;
314 (x) Piminodine;
315 (y) Racemethorphan;
316 (z) Racemorphan;
317 (aa) Remifentanil;
318 (bb) Sufentanil;
319 (cc) Tapentadol;
320 (3) Any material, compound, mixture, or preparation which contains any quantity of the
321 following substances having a stimulant effect on the central nervous system:
322 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
323 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
324 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
325 (d) Phenmetrazine and its salts;
326 (e) Methylphenidate;
327 (4) Any material, compound, mixture, or preparation which contains any quantity of the
328 following substances having a depressant effect on the central nervous system, including its salts,
329 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
330 is possible within the specific chemical designation:
331 (a) Amobarbital;
332 (b) Glutethimide;
333 (c) Pentobarbital;
334 (d) Phencyclidine;
335 (e) Secobarbital;
336 (5) Any material or compound which contains any quantity of nabilone;

337 (6) Any material, compound, mixture, or preparation which contains any quantity of the
338 following substances:

339 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;

340 (b) Immediate precursors to phencyclidine (PCP):

341 a. 1-phenylcyclohexylamine;

342 b. 1-piperidinocyclohexanecarbonitrile (PCC);

343 (7) Any material, compound, mixture, or preparation which contains any quantity of the
344 following alkyl nitrites:

345 (a) Amyl nitrite;

346 (b) Butyl nitrite.

347 5. The department of health and senior services shall place a substance in Schedule III
348 if it finds that:

349 (1) The substance has a potential for abuse less than the substances listed in Schedules
350 I and II;

351 (2) The substance has currently accepted medical use in treatment in the United States;
352 and

353 (3) Abuse of the substance may lead to moderate or low physical dependence or high
354 psychological dependence.

355 6. The controlled substances listed in this subsection are included in Schedule III:

356 (1) Any material, compound, mixture, or preparation which contains any quantity of the
357 following substances having a potential for abuse associated with a stimulant effect on the
358 central nervous system:

359 (a) Benzphetamine;

360 (b) Chlorphentermine;

361 (c) Clortermine;

362 (d) Phendimetrazine;

363 (2) Any material, compound, mixture or preparation which contains any quantity or salt
364 of the following substances or salts having a depressant effect on the central nervous system:

365 (a) Any material, compound, mixture or preparation which contains any quantity or salt
366 of the following substances combined with one or more active medicinal ingredients:

367 a. Amobarbital;

368 b. Secobarbital;

369 c. Pentobarbital;

370 (b) Any suppository dosage form containing any quantity or salt of the following:

371 a. Amobarbital;

372 b. Secobarbital;

- 373 c. Pentobarbital;
- 374 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
375 salt;
- 376 (d) Chlorhexadol;
- 377 (e) Embutramide;
- 378 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
379 a drug product for which an application has been approved under Section 505 of the federal
380 Food, Drug, and Cosmetic Act;
- 381 (g) Ketamine, its salts, isomers, and salts of isomers;
- 382 (h) Lysergic acid;
- 383 (i) Lysergic acid amide;
- 384 (j) Methyprylon;
- 385 (k) Sulfondiethylmethane;
- 386 (l) Sulfonethylmethane;
- 387 (m) Sulfonmethane;
- 388 (n) Tiletamine and zolazepam or any salt thereof;
- 389 (3) Nalorphine;
- 390 (4) Any material, compound, mixture, or preparation containing limited quantities of any
391 of the following narcotic drugs or their salts:
- 392 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
393 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
394 of opium;
- 395 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
396 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
397 therapeutic amounts;
- 398 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
399 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
400 isoquinoline alkaloid of opium;
- 401 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
402 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
403 ingredients in recognized therapeutic amounts;
- 404 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
405 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
406 recognized therapeutic amounts;

407 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
408 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
409 ingredients in recognized therapeutic amounts;

410 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
411 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
412 active nonnarcotic ingredients in recognized therapeutic amounts;

413 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
414 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
415 amounts;

416 (5) Any material, compound, mixture, or preparation containing any of the following
417 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

418 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
419 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
420 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
421 expressly intended for administration through implants to cattle or other nonhuman species and
422 which has been approved by the Secretary of Health and Human Services for that administration.
423 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
424 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
425 meaning of this subdivision. Unless specifically excepted or unless listed in another schedule,
426 any material, compound, mixture or preparation containing any quantity of the following
427 substances, including its salts, esters and ethers:

- 428 (a) $3\beta,17$ -dihydroxy- 5α -androstane;
- 429 (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
- 430 (c) 5α -androstan- $3,17$ -dione;
- 431 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 432 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 433 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 434 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 435 (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
- 436 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);
- 437 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);
- 438 (k) Bolasterone ($7\alpha,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- 439 (l) Boldenone (17β -hydroxyandrost-1,4,-diene-3-one);
- 440 (m) Boldione;
- 441 (n) Calusterone ($7\beta,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- 442 (o) Clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);

- 443 (p) D e h y d r o c h l o r o m e t h y l t e s t o s t e r o n e
 444 (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-dien-3-one);
 445 (q) Desoxymethyltestosterone;
 446 (r) Δ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-3-one);
 447 (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
 448 (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
 449 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
 450 (v) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
 451 (w) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
 452 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostan[2,3-c]-furazan);
 453 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
 454 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
 455 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
 456 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
 457 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
 458 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
 459 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
 460 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
 461 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstan-3-one);
 462 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstan-3-one);
 463 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene);
 464 (j j) 1 7 α - m e t h y l - 4 - h y d r o x y n a n d r o l o n e
 465 (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);
 466 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
 467 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
 468 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
 469 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
 470 (o o) 1 7 α - m e t h y l - Δ 1 - d i h y d r o t e s t o s t e r o n e
 471 (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
 472 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
 473 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
 474 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
 475 (ss) 19-nor-4,9(10)-androstadienedione;
 476 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
 477 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
 478 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

- 479 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 480 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
- 481 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 482 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
- 483 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
- 484 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
- 485 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
- 486 (d d d) O x y m e t h a l o n e
- 487 (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-one);
- 488 (eee) Stanazolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
- 489 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
- 490 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
- 491 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
- 492 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
- 493 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
- 494 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
- 495 subdivision, except an anabolic steroid which is expressly intended for administration through
- 496 implants to cattle or other nonhuman species and which has been approved by the Secretary of
- 497 Health and Human Services for that administration;
- 498 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
- 499 United States Food and Drug Administration approved drug product;
- 500 (8) **Any compound, mixture, or preparation containing any detectable quantity of**
- 501 **ephedrine, phenylpropanolamine, or pseudoephedrine, or any of their salts or optical**
- 502 **isomers, or salts of optical isomers, except any dietary supplements, herbs, or natural**
- 503 **products, including concentrates or extracts, that are not otherwise prohibited by law and**
- 504 **that contain naturally occurring ephedrine alkaloids in a matrix of organic material such**
- 505 **that the substances do not exceed fifteen percent of the total weight of the dietary**
- 506 **supplement, herb, or natural product;**
- 507 (9) **Upon written application of a manufacturer, the department of health and**
- 508 **senior services may exempt by rule any product containing any compound, mixture, or**
- 509 **preparation containing any detectable quantity of ephedrine, phenlypropanolamine, or**
- 510 **pseudoephedrine, or any of their salts or optical isomers, or salts of optical isomers from**
- 511 **the application of all or any part of sections 195.010 to 195.320 because the product is**
- 512 **proven to not be feasible for the conversion of the active ingredient into methamphetamine**
- 513 **or its salts or precursors. For purposes of this subdivision, "proven" includes but is not**
- 514 **limited to the fact that the compound, mixture, or preparation releases less than five**

515 **percent of the active ingredient used for conversion into methamphetamine or its salts or**
516 **precursors. Upon notification from the state highway patrol that the patrol has probable**
517 **cause to believe that a product exempted under this subdivision is feasible for the**
518 **conversion of the active ingredient into methamphetamine or its salts or precursors, the**
519 **department may issue an emergency rule revoking the exemption for the product pending**
520 **a full hearing;**

521 (10) The department of health and senior services may except by rule any compound,
522 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
523 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
524 195.320 if the compound, mixture, or preparation contains one or more active medicinal
525 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
526 admixtures are included therein in combinations, quantity, proportion, or concentration that
527 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
528 the central nervous system.

529 7. The department of health and senior services shall place a substance in Schedule IV
530 if it finds that:

531 (1) The substance has a low potential for abuse relative to substances in Schedule III;
532 (2) The substance has currently accepted medical use in treatment in the United States;
533 and

534 (3) Abuse of the substance may lead to limited physical dependence or psychological
535 dependence relative to the substances in Schedule III.

536 8. The controlled substances listed in this subsection are included in Schedule IV:

537 (1) Any material, compound, mixture, or preparation containing any of the following
538 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
539 as set forth below:

540 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
541 of atropine sulfate per dosage unit;

542 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
543 propionoxybutane);

544 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
545 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
546 upon the compound, mixture or preparation valuable medicinal qualities other than those
547 possessed by the narcotic drug alone:

548 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
549 one hundred grams;

550 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
551 or per one hundred grams;

552 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
553 or per one hundred grams;

554 (2) Any material, compound, mixture or preparation containing any quantity of the
555 following substances, including their salts, isomers, and salts of isomers whenever the existence
556 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 557 (a) Alprazolam;
- 558 (b) Barbital;
- 559 (c) Bromazepam;
- 560 (d) Camazepam;
- 561 (e) Chloral betaine;
- 562 (f) Chloral hydrate;
- 563 (g) Chlordiazepoxide;
- 564 (h) Clobazam;
- 565 (i) Clonazepam;
- 566 (j) Clorazepate;
- 567 (k) Clotiazepam;
- 568 (l) Cloxazolam;
- 569 (m) Delorazepam;
- 570 (n) Diazepam;
- 571 (o) Dichloralphenazone;
- 572 (p) Estazolam;
- 573 (q) Ethchlorvynol;
- 574 (r) Ethinamate;
- 575 (s) Ethyl loflazepate;
- 576 (t) Fludiazepam;
- 577 (u) Flunitrazepam;
- 578 (v) Flurazepam;
- 579 (w) Fospropofol;
- 580 (x) Halazepam;
- 581 (y) Haloxazolam;
- 582 (z) Ketazolam;
- 583 (aa) Loprazolam;
- 584 (bb) Lorazepam;
- 585 (cc) Lormetazepam;

- 586 (dd) Mebutamate;
587 (ee) Medazepam;
588 (ff) Meprobamate;
589 (gg) Methohexital;
590 (hh) Methylphenobarbital (mephobarbital);
591 (ii) Midazolam;
592 (jj) Nimetazepam;
593 (kk) Nitrazepam;
594 (ll) Nordiazepam;
595 (mm) Oxazepam;
596 (nn) Oxazolam;
597 (oo) Paraldehyde;
598 (pp) Petrichloral;
599 (qq) Phenobarbital;
600 (rr) Pinazepam;
601 (ss) Prazepam;
602 (tt) Quazepam;
603 (uu) Temazepam;
604 (vv) Tetrazepam;
605 (ww) Triazolam;
606 (xx) Zaleplon;
607 (yy) Zolpidem;
608 (zz) Zopiclone;
609 (3) Any material, compound, mixture, or preparation which contains any quantity of the
610 following substance including its salts, isomers and salts of isomers whenever the existence of
611 such salts, isomers and salts of isomers is possible: fenfluramine;
612 (4) Any material, compound, mixture or preparation containing any quantity of the
613 following substances having a stimulant effect on the central nervous system, including their
614 salts, isomers and salts of isomers:
615 (a) Cathine ((+)-norpseudoephedrine);
616 (b) Diethylpropion;
617 (c) Fencamfamin;
618 (d) Fenproporex;
619 (e) Mazindol;
620 (f) Mefenorex;
621 (g) Modafinil;

- 622 (h) Pemoline, including organometallic complexes and chelates thereof;
623 (i) Phentermine;
624 (j) Pipradrol;
625 (k) Sibutramine;
626 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
627 (5) Any material, compound, mixture or preparation containing any quantity of the
628 following substance, including its salts:
629 (a) butorphanol;
630 (b) pentazocine;
631 (6) [Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
632 is the only active medicinal ingredient;
633 (7)] The department of health and senior services may except by rule any compound,
634 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
635 subsection from the application of all or any part of sections 195.010 to 195.320 if the
636 compound, mixture, or preparation contains one or more active medicinal ingredients not having
637 a depressant effect on the central nervous system, and if the admixtures are included therein in
638 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
639 substances which have a depressant effect on the central nervous system.
640 9. The department of health and senior services shall place a substance in Schedule V
641 if it finds that:
642 (1) The substance has low potential for abuse relative to the controlled substances listed
643 in Schedule IV;
644 (2) The substance has currently accepted medical use in treatment in the United States;
645 and
646 (3) The substance has limited physical dependence or psychological dependence liability
647 relative to the controlled substances listed in Schedule IV.
648 10. The controlled substances listed in this subsection are included in Schedule V:
649 (1) Any compound, mixture or preparation containing any of the following narcotic
650 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
651 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
652 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
653 qualities other than those possessed by the narcotic drug alone:
654 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
655 twenty-five micrograms of atropine sulfate per dosage unit;
656 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
657 one hundred grams;

658 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
659 micrograms of atropine sulfate per dosage unit;

660 (2) Any material, compound, mixture or preparation which contains any quantity of the
661 following substance having a stimulant effect on the central nervous system including its salts,
662 isomers and salts of isomers: pyrovalerone;

663 (3) [Any compound, mixture, or preparation containing any detectable quantity of
664 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
665 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
666 isomers, or salts of optical isomers;

667 (4)] Unless specifically exempted or excluded or unless listed in another schedule, any
668 material, compound, mixture, or preparation which contains any quantity of the following
669 substances having a depressant effect on the central nervous system, including its salts:

670 (a) Lacosamide;

671 (b) Pregabalin.

672 11. If any compound, mixture, or preparation [as specified in subdivision (3) of
673 subsection 10 of this section] is dispensed, sold, or distributed in a pharmacy without a
674 prescription:

675 (1) All packages of any compound, mixture, or preparation containing any detectable
676 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
677 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
678 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
679 registered pharmacy technician; and

680 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
681 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
682 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
683 shall be at least eighteen years of age; and

684 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
685 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
686 or preparation to furnish suitable photo identification that is issued by a state or the federal
687 government or a document that, with respect to identification, is considered acceptable and
688 showing the date of birth of the person;

689 (4) The seller shall deliver the product directly into the custody of the purchaser.

690 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
691 implement and maintain an electronic log of each transaction. Such log shall include the
692 following information:

693 (1) The name, address, and signature of the purchaser;

- 694 (2) The amount of the compound, mixture, or preparation purchased;
695 (3) The date and time of each purchase; and
696 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
697 technician who dispensed the compound, mixture, or preparation to the purchaser.
- 698 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
699 or preparation [as specified in subdivision (3) of subsection 10 of this section] in accordance with
700 transmission methods and frequency established by the department by regulation;
- 701 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
702 greater than those specified in this chapter.
- 703 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
704 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
705 where the public is not permitted.
- 706 16. Any person who knowingly or recklessly violates the provisions of subsections 11
707 to 15 of this section is guilty of a class A misdemeanor.
- 708 17. The scheduling of substances specified in subdivision [(3)] (8) of subsection [10] 6
709 of this section and subsections 11, 12, 14, and 15 of this section shall not apply to any
710 compounds, mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any
711 compound, mixture, or preparation specified in subdivision [(3)] (8) of subsection [10] 6 of this
712 section which must be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
- 713 18. The manufacturer of a drug product or another interested party may apply with the
714 department of health and senior services for an exemption from this section. The department of
715 health and senior services may grant an exemption by rule from this section if the department
716 finds the drug product is not used in the illegal manufacture of methamphetamine or other
717 controlled or dangerous substances. The department of health and senior services shall rely on
718 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
719 proposed product can be used to manufacture illicit controlled substances.
- 720 19. The department of health and senior services shall revise and republish the schedules
721 annually.
- 722 20. The department of health and senior services shall promulgate rules under chapter
723 536 regarding the security and storage of Schedule V controlled substances, as described in
724 subdivision [(3)] (8) of subsection [10] 6 of this section, for distributors as registered by the
725 department of health and senior services.
- 726 21. Logs of transactions required to be kept and maintained by this section and section
727 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
728 the person whose transactions are recorded in the logs.
- 729 **22. This section shall be known as the "Meth Lab Elimination Act".**

Section B. The amendments to section 195.017 of this act shall expire on August 28,
2 2014.

✓